NIKI (Niki BioSolutions) Other Stockholders Equity: $0.05 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NIKI Niki BioSolutions Inc NIKI
34 GF Score
Price $6.23
! 1 Warning Sign
View Full Analysis

What is Niki BioSolutions Other Stockholders Equity?

Niki BioSolutions NIKI -4.76% 34 Other Stockholders Equity is $0.05 Mil as of Dec. 2025. GuruFocus rates NIKI with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Niki BioSolutions's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $0.05 Mil.

Niki BioSolutions's quarterly Other Stockholders Equity increased from Jun. 2025 ($-0.00 Mil) to Sep. 2025 ($-0.00 Mil) and increased from Sep. 2025 ($-0.00 Mil) to Dec. 2025 ($0.05 Mil).

Niki BioSolutions's annual Other Stockholders Equity increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) and increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.05 Mil).

Niki BioSolutions Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Niki BioSolutions's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Niki BioSolutions Other Stockholders Equity Chart

Niki BioSolutions Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.05

Niki BioSolutions Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.05 0.05
NIKI
34GF Score
Niki BioSolutions Inc NIKI
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Niki BioSolutions Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.05 Mil mean?
Niki BioSolutions (NIKI) has a Other Stockholders Equity of $0.05 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Niki BioSolutions and its competitors.
Is Niki BioSolutions' Other Stockholders Equity too high?
Niki BioSolutions' current Other Stockholders Equity is $0.05 Mil. Overall, Niki BioSolutions has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Niki BioSolutions' Other Stockholders Equity compare to KAPA and LIMN?
Niki BioSolutions' Other Stockholders Equity of $0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Niki BioSolutions and its competitors. Niki BioSolutions's current Other Stockholders Equity is $0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niki BioSolutions stock overvalued right now?
Niki BioSolutions (NIKI) has a current Other Stockholders Equity of $0.05 Mil. The current Other Stockholders Equity is $0.05 Mil. Niki BioSolutions' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Niki BioSolutions (NIKI), the current Other Stockholders Equity is $0.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Niki BioSolutions Business Description

Address 17 Hanover Square, London, GBR, W1S 1BN
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
34GF Score

Get the complete analysis for NIKI

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.23
Price